Soluble guanylate cyclase activators

US9365574B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Subharekha Raghavan · Teaneck, US
• John E. Stelmach · Westfield, US
• Cameron Smith · Lawrenceville, US
• Hong Li · Edison, US
• Alan Whitehead · Scotch Plains, US
• Sherman T. Waddell · Westfield, US
• Yi-Heng Chen · Whippany, US
• Shouwu Miao · Edison, US
• Olga Ornoski · Teaneck, US
• Joie Garfunkle · Metuchen, US
• Xibin Liao · Edison, US
• Jiang Chang · Beijing, CN
• Xiaoqing Han · Edison, US
• Jian Guo · Lawrence, US
• Jonathan Groeper · Metuchen, US
• Linda Brockunier · Orange, US
• Keith Rosauer · New Hampton, US
• Emma R. Parmee · Scotch Plains, US

Key dates

• Filing date: May 24, 2011
• Grant date: Jun 14, 2016
• Expiry date: Apr 12, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof.